Cancer News and Research

Latest Cancer News and Research

Radiation therapy may not benefit many older lung cancer patients

A new study has found that many older lung cancer patients get treatments that may not help them live longer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest that physicians should not routinely use radiation after surgery to treat lung cancer that is advanced but has not widely spread, at least in older patients.

13 Feb 2012

Study demonstrates dynamic genetic changes in ovarian cancers between diagnosis and recurrence

There is a need to analyze tumor specimens at the time of ovarian cancer recurrence, according to a new study published in Molecular Cancer Therapeutics.

13 Feb 2012

First Edition: February 13, 2012

Today's early morning highlights from the major news organizations preview President Barack Obama's budget, which will be released today, and examine the lingering controversy over mandates on contraceptive coverage.

13 Feb 2012

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the fourth quarter and full year 2011 and provided an update on development programs.

13 Feb 2012

OncoSec to commence OMS ElectroImmunotherapy Phase II trial in MCC

OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma.

13 Feb 2012

PORT may not prolong life in older people with NSCLC

Researchers from Mount Sinai School of Medicine have found that post-operative radiation therapy (PORT), a controversial yet frequently administered treatment for lung cancer, may not prolong life in older people with locally advanced disease.

13 Feb 2012

SFU cell biologist to talk at AJAS conference on Feb. 16

Lynne Quarmby, a Simon Fraser University scientist with a passion for promoting the importance of science to life's sustenance, will have a captive audience during the world's largest science fair in Vancouver.

13 Feb 2012

BIO President issues statement on FDA guidance for biosimilars

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood issued the following statement regarding the newly released U.S. Food and Drug Administration (FDA) guidance for the review and approval of biosimilars.

13 Feb 2012

Benefits of long-term Kineret therapy in people with NOMID

A new study shows that Kineret (anakinra), a medication approved for the treatment of rheumatoid arthritis, is effective in stopping the progression of organ damage in people with neonatal-onset multisystem inflammatory disease.

13 Feb 2012

Discovery sheds light on what happens in cells when DNA is damaged

A research group in the Faculty of Medicine & Dentistry at the University of Alberta is hoping its latest discovery could one day be used to develop new therapies that target certain types of cancers.

13 Feb 2012

Researchers discover a startling feature of early brain development

Researchers at the Salk Institute have discovered a startling feature of early brain development that helps to explain how complex neuron wiring patterns are programmed using just a handful of critical genes. The findings, published February 3 in Cell, may help scientists develop new therapies for neurological disorders, such as amyotrophic lateral sclerosis (ALS), and provide insight into certain cancers.

13 Feb 2012

Bexarotene appears to help clear out excess plaque in Alzheimer's

"In the last eight days, scientists have delivered a powerful one-two punch in the fight to defeat Alzheimer's disease," said Stacy Pagos Haller, President and CEO of the American Health Assistance Foundation (AHAF), a nonprofit that identifies and funds exceptionally high-impact research worldwide through its Alzheimer's Disease Research program.

13 Feb 2012

Molecular secrets behind halofuginone's power

For roughly two thousand years, Chinese herbalists have treated Malaria using a root extract, commonly known as Chang Shan, from a type of hydrangea that grows in Tibet and Nepal. More recent studies suggest that halofuginone, a compound derived from this extract's bioactive ingredient, could be used to treat many autoimmune disorders as well. Now, researchers from the Harvard School of Dental Medicine have discovered the molecular secrets behind this herbal extract's power.

13 Feb 2012

Incident malignancy four times higher among children with JIA

New research reports that incident malignancy among children with juvenile idiopathic arthritis (JIA) is four times higher than in those without the disease. Findings now available in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR), suggest JIA treatment, such as tumor necrosis factor (TNF) inhibitors, does not necessarily explain the development of cancer in this pediatric population.

13 Feb 2012

KSU, St. Michael's receive U.S. patent to use BRCA1 gene for cardiovascular disease

St. Michael's Hospital and King Saud University have received their first joint U.S. patent to use the BRCA1 gene as a therapy for cardiovascular disease.

13 Feb 2012

OptumHealth names Women & Infants as Center of Excellence for Neonatal Care

For the sixth consecutive year, Women & Infants Hospital of Rhode Island has been named a Center of Excellence for Neonatal Care by the Clinical Sciences Institute of OptumHealth, an independent audit company.

13 Feb 2012

Curcumin may block growth of castrate-resistant prostate tumors

Curcumin, an active component of the Indian curry spice turmeric, may help slow down tumor growth in castration-resistant prostate cancer patients on androgen deprivation therapy (ADT), a study from researchers at Jefferson's Kimmel Cancer Center suggests.

13 Feb 2012

Cancer drug bexarotene effective in mouse model of Alzheimer’s

Case Western Reserve University School of Medicine neuroscientist Gary Landreth and colleagues reported Thursday that the drug - bexarotene quickly cleared away beta-amyloid plaque, believed to cause the cognitive deficits of Alzheimer's disease, from the brains of genetically engineered mice.

12 Feb 2012

Preliminary results from Soligenix SGX201 Phase 1/2 trial on acute radiation enteritis

Soligenix, Inc., a development stage biopharmaceutical company, announced preliminary results today from a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.

10 Feb 2012

Exelixis prices underwritten public offering of common stock

Exelixis, Inc. today announced the pricing of its underwritten public offering of 11,000,000 shares of newly issued common stock at a price to the public of $5.50 per share.

10 Feb 2012